Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...

Report commissioned by govt analysed cost-effectiveness of 2 medicines, comparing them to to chemo in patients with newly ...

Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications ...

Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...

Olverembatinib (HQP1351), a novel, next-generation TKI and the first third-generation BCR-ABL1 TKI, has been approved in ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

An application was submitted to the European Medicines Agency seeking approval for treatment with sugemalimab in stage 3 ...

Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

CStone Pharmaceuticals ('CStone', HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Type II variation application to the ...

A multivariate analysis confirmed the independent prognostic significance of both landmark and longitudinal MRD.

DelveInsight's "VITRAKVI Market Size, Forecast, and Market Insight Report" highlights the details around VITRAKVI, a TRK, ...

and has shown anti-tumor effects in mice with intracranial tumors driven by TRKA and ALK. The recommended ROZLYTREK dosage for ROS1-positive NSCLC is 600 mg once daily, with or without food ...